Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgios V Georgakis

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Expert Review of Anticancer Therapy|December 27, 2005
From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapyGeorgios V Georgakis, Anas Younes
Cancer Treatment and Research|October 8, 2005
Cytokines and lymphomasGeorgios V Georgakis, Anas Younes
Future Oncology (London, England)|March 25, 2006
Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyondGeorgios V Georgakis, Anas Younes
British Journal of Haematology|August 24, 2006
The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9Georgios V Georgakis, Yang Li, Anas Younes
Future Oncology (London, England)|August 23, 2006
Hodgkin's lymphoma: molecular targets and novel treatment strategiesVictor Yazbeck, Georgios V Georgakis, Amanda Wedgwood, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2006
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinomaMamoun Younes, Georgios V Georgakis, Mahdis Rahmani, et al.
Blood|December 6, 2003
c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphomaGeorge Z Rassidakis, Georgios V Georgakis, Anas Younes, et al.
Scientific Reports|July 2, 2024
Design and radiosynthesis of class-IIa HDAC inhibitor with high molar activity via repositioning the <sup>18</sup>F-radiolabelSulan Xu, Chun-Han Huang, Christopher Eyermann, et al.
Experimental Hematology|December 13, 2006
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expressionGeorgios V Georgakis, Yang Li, Georgios Z Rassidakis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 24, 2004
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosisGeorge Z Rassidakis, Georgios V Georgakis, Mauricio Oyarzo, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Expert Review of Anticancer Therapy|December 27, 2005
From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapyGeorgios V Georgakis, Anas Younes
Cancer Treatment and Research|October 8, 2005
Cytokines and lymphomasGeorgios V Georgakis, Anas Younes
Future Oncology (London, England)|March 25, 2006
Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyondGeorgios V Georgakis, Anas Younes
British Journal of Haematology|August 24, 2006
The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9Georgios V Georgakis, Yang Li, Anas Younes
Future Oncology (London, England)|August 23, 2006
Hodgkin's lymphoma: molecular targets and novel treatment strategiesVictor Yazbeck, Georgios V Georgakis, Amanda Wedgwood, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2006
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinomaMamoun Younes, Georgios V Georgakis, Mahdis Rahmani, et al.
Blood|December 6, 2003
c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphomaGeorge Z Rassidakis, Georgios V Georgakis, Anas Younes, et al.
Scientific Reports|July 2, 2024
Design and radiosynthesis of class-IIa HDAC inhibitor with high molar activity via repositioning the <sup>18</sup>F-radiolabelSulan Xu, Chun-Han Huang, Christopher Eyermann, et al.
Experimental Hematology|December 13, 2006
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expressionGeorgios V Georgakis, Yang Li, Georgios Z Rassidakis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 24, 2004
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosisGeorge Z Rassidakis, Georgios V Georgakis, Mauricio Oyarzo, et al.
Pageof 3